Literature DB >> 13679467

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises.

Biff F Palmer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 13679467     DOI： 10.1093/ndt/gfg282

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  10 in total

1.  The positive predictive value of a hyperkalemia diagnosis in automated health care data.

Authors:  Marsha A Raebel; Michael L Smith; Gwyn Saylor; Leslie A Wright; Craig Cheetham; Christopher M Blanchette; Stanley Xu
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11       Impact factor: 2.890

Review 2.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Renal impairment, mild hyperkalemia and atrioventricular conduction blockade: a potentially hazardous combination.

Authors:  Mohamed Osama Hegazi; Faisal Saleh; Abdalla Nawara
Journal:  Int J Biometeorol       Date:  2015-01-17       Impact factor: 3.787

4.  Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.

Authors:  Giacomo D Simonetti; Rodo O von Vigier; Martin Konrad; Mattia Rizzi; Emilio Fossali; Mario G Bianchetti
Journal:  Pediatr Nephrol       Date:  2006-06-27       Impact factor: 3.714

5.  Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes.

Authors:  Edouard L Fu; Marco Trevisan; Catherine M Clase; Marie Evans; Bengt Lindholm; Joris I Rotmans; Merel van Diepen; Friedo W Dekker; Juan-Jesus Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2019-08-08       Impact factor: 8.237

6.  Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.

Authors:  Marsha A Raebel; Colleen Ross; Stanley Xu; Douglas W Roblin; Craig Cheetham; Christopher M Blanchette; Gwyn Saylor; David H Smith
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

7.  Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.

Authors:  Yoshifuru Tamura; Masahiro Kosuga; Masahiro Yamashita; Satoru Tomioka; Michiko Sasaki; Tomoyuki Hikita; Hideaki Nakajima; Kenichiro Kojima; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2008-03-05       Impact factor: 2.801

Review 8.  Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: role of antihypertensive drug management.

Authors:  Giacomo D Simonetti; Laura Santoro; Alessandra Ferrarini; Laura Crosazzo-Franscini; Emilio Fossali; Mario G Bianchetti
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

9.  Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Authors:  Sadayoshi Ito; Minoru Satoh; Yuko Tamaki; Hiromi Gotou; Alan Charney; Naoko Okino; Mizuki Akahori; Jack Zhang
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

10.  Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.

Authors:  Eugenia Espinel; Jorge Joven; Iván Gil; Pilar Suñé; Berta Renedo; Joan Fort; Daniel Serón
Journal:  BMC Res Notes       Date:  2013-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.